These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 17003060)

  • 1. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
    Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
    Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
    Gould KA; Pan XS; Kerns RJ; Fisher LM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates.
    Bansal S; Tandon V
    Int J Antimicrob Agents; 2011 Mar; 37(3):253-5. PubMed ID: 21236644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of antimicrobial resistance in enteroaggregative Escherichia coli and enterotoxigenic Escherichia coli causing traveller's diarrhoea.
    Mendez Arancibia E; Pitart C; Ruiz J; Marco F; Gascón J; Vila J
    J Antimicrob Chemother; 2009 Aug; 64(2):343-7. PubMed ID: 19474067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization of ciprofloxacin-resistant Salmonella enterica serovar Typhi and Paratyphi A causing enteric fever in India.
    Gaind R; Paglietti B; Murgia M; Dawar R; Uzzau S; Cappuccinelli P; Deb M; Aggarwal P; Rubino S
    J Antimicrob Chemother; 2006 Dec; 58(6):1139-44. PubMed ID: 17071955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage.
    Chen CR; Malik M; Snyder M; Drlica K
    J Mol Biol; 1996 May; 258(4):627-37. PubMed ID: 8636997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
    Chenia HY; Pillay B; Pillay D
    J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
    Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
    J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
    Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
    J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
    Yoon EJ; Lee CY; Shim MJ; Min YH; Kwon AR; Lee J; Choi EC
    Chemotherapy; 2010; 56(2):153-7. PubMed ID: 20407243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the cell wall on ciprofloxacin susceptibility in selected wild-type Gram-negative and Gram-positive bacteria.
    Berlanga M; Montero MT; Hernández-Borrell J; Viñas M
    Int J Antimicrob Agents; 2004 Jun; 23(6):627-30. PubMed ID: 15194135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of mutation distribution in DNA gyrase and topoisomerase IV genes in ciprofloxacin-non-susceptible Enterobacteriaceae isolated from blood cultures in a tertiary care university hospital in South Korea, 2005-2010.
    Nam YS; Cho SY; Yang HY; Park KS; Jang JH; Kim YT; Jeong JW; Suh JT; Lee HJ
    Int J Antimicrob Agents; 2013 Feb; 41(2):126-9. PubMed ID: 23265914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
    Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
    Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.